NCT05410301 2023-04-21
Golden Halo, Static Magnetic and Electric Field Device, in Recurrent Glioblastoma
University of Iowa
Phase NA Withdrawn
Clinical Trials
7 trialsNCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00984438 2019-11-25
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
Phase 1/2 Withdrawn
NCT01788280 2018-02-07
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
University of Utah
Phase 2 Withdrawn
NCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00904852 2009-05-20
Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After Radiation and Temozolomide in Patients With Newly Diagnosed With Glioblastoma Multiforme
Millennium Pharmaceuticals, Inc.
Phase 1 Withdrawn